The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.
Only a minority of patients with low-risk prostate cancer needs treatment, but the methods for optimal selection of patients for treatment are not established. This article describes the Study of Active Monitoring in Sweden (SAMS), which aims to improve those methods.
SAMS is a prospective, multicentre study of active surveillance for low-risk prostate cancer. It consists of a randomized part comparing standard rebiopsy and follow-up with an extensive initial rebiopsy coupled with less intensive follow-up and no further scheduled biopsies (SAMS-FU), as well as an observational part (SAMS-ObsQoL). Quality of life is assessed with questionnaires and compared with patients receiving primary curative treatment. SAMS-FU is planned to randomize 500 patients and SAMS-ObsQoL to include at least 500 patients during 5 years. The primary endpoint is conversion to active treatment. The secondary endpoints include symptoms, distant metastases and mortality. All patients will be followed for 10-15 years.
Inclusion started in October 2011. In March 2013, 148 patients were included at 13 Swedish urological centres.
It is hoped that the results of SAMS will contribute to fewer patients with indolent, low-risk prostate cancer receiving unnecessary treatment and more patients on active surveillance who need treatment receiving it when the disease is still curable. The less intensive investigational follow-up in the SAMS-FU trial would reduce the healthcare resources allocated to this large group of patients if it replaced the present standard schedule.
Notes
Cites: J Urol. 2007 Sep;178(3 Pt 1):833-717631355
Cites: J Natl Cancer Inst. 2006 Aug 16;98(16):1128-3316912265
Cites: J Urol. 2006 Sep;176(3):868-7416890642
Cites: N Engl J Med. 2003 Jul 17;349(3):215-2412824459
Cites: J Natl Cancer Inst. 2003 Jun 18;95(12):868-7812813170
Cites: Prostate Cancer Prostatic Dis. 2007;10(3):237-4117387320
Cites: Cancer. 2008 Oct 15;113(8):2068-7218792067
Cites: J Urol. 2009 Nov;182(5):2274-819758635
Cites: J Urol. 2010 Jan;183(1):126-3119913257
Cites: J Urol. 2010 Jan;183(1):138-4319913808
Cites: J Clin Oncol. 2010 Jan 1;28(1):126-3119917860